Ninlaro Combo Fails to Extend New Myeloma Patients’ Survival Without Disease Worsening
A combination of Ninlaro (ixazomib), Revlimid (lenalidomide),…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
FDA Names Arcellx’s Cell Therapy CART-ddBCMA Orphan Drug for Multiple Myeloma
Arcellx’s CART-ddBCMA — a CAR T-cell…
Gains in 5-Year Survival with Stem Cell Transplant Evident Since Late ’90s
The long-term survival of people with…
Empliciti Combo Fails to Stem Progression of Newly Diagnosed Multiple Myeloma
Empliciti (elotuzumab), in combination with Revlimid…
RRMM Trial Testing Safety, Efficacy of TAK-169 Therapy Doses First Patient
The first patient has been dosed in…
Pediatric Rare Disease Therapies Increase, But Most Repurposed, Study Finds
The number of treatments for children with rare diseases has…
